HIGHOutside partyProduct / Revenue mix
Suboxone
“10-K Item 1: 'We are the sole and exclusive supplier and manufacturer of Suboxone and have produced over 3.0 billion doses of Suboxone since its launch in 2010.'”
AQST · Concentration risk · 10-K extracted
Aquestive Therapeutics (AQST) concentration risks
Updated
The most significant concentration Aquestive Therapeutics discloses is Suboxone, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Aquestive Therapeutics’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 1 disclosed concentration
HIGH1
MEDIUM0
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-07-06Aquestive Therapeutics' concentration risk sits in a single product relationship: the company serves as sole and exclusive supplier and manufacturer of Suboxone, a product for which it has produced over 3.0 billion doses since its 2010 launch. This is a high-size exposure — the disclosed reliance sits at the top of the scale — and its character is a dependency rather than a purely structural feature, meaning outcomes hinge on the continuation and terms of this single manufacturing relationship rather than on diversified revenue streams. The scale of historical production speaks to an established, long-running commercial relationship, which somewhat tempers the idiosyncratic risk of a single-product dependency, but it does not change the underlying math: a disruption to this arrangement — whether commercial, regulatory, or competitive — would have an outsized effect on the business given no other concentration exposures are disclosed to offset it. For an educated investor, this is the single factor most likely to move the verdict, since it is both high in disclosed size and the only concentration risk identified in the filing, with no supplier, customer, or geographic diversification disclosed to counterbalance it.
For the engine’s reasoning on AQST’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Drug Manufacturers - Specialty & Generic
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ANIP | ANI Pharmaceuticals, Inc. | 2 | 1 | 0 | 3 |
| AMLX | Amylyx Pharmaceuticals, Inc. | 2 | 0 | 0 | 2 |
| AMPH | Amphastar Pharmaceuticals, Inc. | 1 | 2 | 1 | 4 |
| AMRX | Amneal Pharmaceuticals, Inc. | 1 | 1 | 0 | 2 |
| AQST● | Aquestive Therapeutics, Inc. | 1 | 0 | 0 | 1 |
| ALKS | Alkermes plc | 0 | 1 | 1 | 2 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.